Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

MNKD $0.55 0.0700 +14.58%
CASC $5.50 0.5300 +10.66%
BLCM $18.72 1.7400 +10.25%
SYRS $15.47 1.3900 +9.87%
CTIC $0.49 0.0430 +9.73%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

TRIL $6.70 -0.5000 -6.94%
MRTX $5.05 -0.2000 -3.81%
BPMC $27.01 -0.9900 -3.54%
RXDX $5.95 -0.2000 -3.25%
LBIO $6.00 -0.2000 -3.23%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next > | Last >>

NantHealth Announces Global Expansion of GPS Cancer; Partners with Sorgente to Expand Availability of GPS Cancer™ to Italy

(NantHealth) Nov 3, 2016 - Community oncologists will now have access to comprehensive tests to help them make better informed clinical decisions aimed at personalizing care for their patients; partnership further expands availability of molecular profiling test internationally.
read corporate press release 



The US Health Care System Should Prepare and Participate in Changing Payment Models

(Cancer Therapy Advisor) Nov 3, 2016 - The United States health care system must learn to deliver high quality health care at lower costs, or it risks driving up annual health care costs to the equivalent of the average US household income, according to Lee N. Newcomer, MD, senior vice president of oncology and genetics at UnitedHealth care.
read article 



CMS 2017 OPPS & MPFS Final Rules: Top-Level Takeaways

(ACCCBuzz) Nov 4, 2016 - This week the Centers for Medicare & Medicaid Services (CMS) released the final CY 2017 Hospital Outpatient Prospective Payment System (OPPS) and Medicare Physician Fee Schedule (MPFS) rules. ACCC is currently analyzing the rules and will hold a webinar for members with more in-depth information in the coming weeks. Below are some key highlights.
read article 



Georgetown Researchers Describe Method to Study Real Time Cancer Invasion

(GUMC) Nov 3, 2016 - A research team at Georgetown Lombardi Comprehensive Cancer Center has described the steps, in both written and video format, that allow cancer investigators to track, in real time, cancer cell invasion and metastasis in transparent zebrafish embryos.
read press release 



University of Alberta Researchers Pinpoint Key Protein Involved in Thyroid Cancer

(Edmonton Journal [Canada]) Nov 2, 2016 - University of Alberta medical researchers say they have taken a big step toward advancing new diagnostics and therapies for thyroid cancer patients because of the identification of a specific protein that drives the disease.
read article 



Tumour Cells In Blood Samples Could Predict Prostate Cancer Spread

(Cancer Research UK/NCRI) Nov 4, 2016 - Researchers have found a group of circulating tumour cells in prostate cancer patient blood samples which are linked to the spread of the disease.
read press release 



A Race Against Time to Diagnose Deadly Weight Loss in Cancer Patients

(MUHC [Montreal, Canada]) Nov 4, 2016 - A study by researchers at the McGill University Health Centre (MUHC), published in Clinical Nutrition, aims to save patient lives by giving doctors a practical tool to easily diagnose cachexia before it becomes irreversible.
read press release 



Breast Cancer Patients Have New Surgery Option with Radioactive Seed

(UC Davis CCC) Nov 3, 2016 - UC Davis Comprehensive Cancer Center now offers a new technique for breast cancer patients undergoing surgery to remove breast cancer that may improve cosmetic outcomes and the patient’s surgery experience.
read press release 



Takeda to Present Broad Range of Clinical Data During 58th American Society of Hematology Annual Meeting

(Yahoo! Finance) Nov 3, 2016 - Demonstrating expertise and leadership in hematologic oncology, presentations include Phase 3 data on ADCETRIS® (brentuximab vedotin) in CD30-positive cutaneous T-cell lymphoma, NINLARO (ixazomib) in relapsed/refractory multiple myeloma and emerging pipeline; presentations underscore Takeda’s ongoing commitment to transform care for patients affected by blood cancers.
read article 



Every Year of Smoking Causes DNA Mutations That Make Cancer More Likely

(Los Angeles Times/Science Now blog) Nov 3, 2016 - Attention smokers: For every year that you continue your pack-a-day habit, the DNA in every cell in your lungs acquires about 150 new mutations.
read article (free registration required) 



Smoking a Pack Per Day Causes 150 Mutations In Every Lung Cell, Research Shows

(Reuters) Nov 3, 2016 - Scientists have found that smoking a pack a day of cigarettes can cause 150 damaging changes to a smoker's lung cells each year.
read article 



Roche Showcases New Clinical Data Across A Variety Of Blood Diseases At American Society Of Hematology 2016 Annual Meeting

(Roche) Nov 3, 2016 - New results from the phase III GALLIUM study which compared Gazyva/Gazyvaro (obinutuzumab) plus chemotherapy to Rituxan/ MabThera (rituximab) plus chemotherapy in previously untreated follicular lymphoma will be presented in the Plenary Scientific Session; new results for Venclexta/Venclyxto(venetoclax) and investigational medicine emicizumab will also be presented at the meeting; US FDA has accepted the Biologics License Application for a subcutaneous formulation of Rituxan®(rituximab/hyaluronidase).
read corporate press release 



Seven Substances Added to 14th Report On Carcinogens

(NIH) Nov 3, 2016 - Five viruses, a chemical, and a metallic element listed in new HHS report.
read press release 



Adverse Events in Trial Dent Hopes for Roche Hemophilia Drug

(Reuters) Nov 2, 2016 - Four patients have suffered serious adverse events in a clinical trial of an experimental hemophilia medicine from Roche, the Swiss group said on Wednesday, clouding prospects for its potential blockbuster product.
read article 



How To Make The Medical Expenditures Panel Survey Even More Useful

(Health Affairs Blog) Nov 2, 2016 - The Medical Expenditures Panel Survey (MEPS) has become a critical asset to health policymakers on both sides of the aisle. The survey, which has been conducted annually by the Agency for Healthcare Research and Quality since 1996, was preceded by two surveys conducted in 1977 and 1986.
read article 



Why Express Scripts CMO Thinks Drug Price Regulation Is a "Bad Idea”

(FORTUNE) Nov 2, 2016 - With recent uproar over drug price hikes by Valeant and Martin Shkreli, healthcare experts have reached a consensus: The system as we know it is officially broken.
read article 



Complete the Free PQRS Reporting Available Through QOPI® by December 31 to Avoid a Two Percent Medicare Reimbursement Cut in 2018

(ASCO in Action) Nov 2, 2016 - In September, ASCO announced its latest offering to oncology practices: the ability to complete all Physician Quality Reporting System (PQRS) requirements through the user-friendly Quality Oncology Practice Initiative (QOPI®) platform at no cost.
read article 



Inivata and N-of-One Partner to Provide Personalized Genomic Interpretation and Clinical Trial Matching for Cancer Patients

(Inivata) Nov 3, 2016 - Inivata, a global clinical cancer genomics company employing a revolutionary approach to circulating tumor DNA (ctDNA) analysis to improve personalized healthcare in oncology, and N-of-One, Inc., a precision medicine oncology decision support company, are pleased to announce a new partnership to support analysis of patient cases for Inivata’s InVision® liquid biopsy product line.
read corporate press release 



Genetic Counselor Mandate Creates a Barrier to BRCA1/2 Testing, New Study Finds

(4-traders) Nov 3, 2016 - Healthcare payer mandates for consulting with a genetic specialist prior to BRCA1/2 genetic testing creates a significant barrier to care, particularly for minority patients, according to research published this week in the Journal of Oncology Practice.
read article 



Four Things Health Execs Should Know About the Oncology Pipeline

(Managed Healthcare Executive) Nov 3, 2016 - Oncology therapeutic and supportive care agents in the development pipeline promise to be more effective, more therapeutically targeted, more personalized—and far more costly, according to industry experts.
read article 



Eisai Latest Cancer Drugmaker To Win UK Approval After Price Cut

(Reuters) Nov 2, 2016 - Cancer drugmakers are cutting prices to ensure their medicines are used routinely on Britain's National Health Service, following the overhaul of a cancer drug funding scheme, with Japan's Eisai the latest to win approval.
read article 



Why Incyte's Shares Could Soon Hit $100

(TheStreet) Nov 2, 2016 - Incyte reported very strong third-quarter results thanks to the company's therapy for certain types of blood cancers, which is being used by more patients.
read article 



This Is The Big Reason America Is Losing The War On Cancer

(FORTUNE) Nov 2, 2016 - Here’s a not uncommon experience in medical care in 2016: A man goes to the doctor. He learns his PSA levels—or the amount of a protein produced by the prostate—are high, which is often the case in men with prostate cancer. The doctor can’t tell him what the patient’s elevated PSA reading means, and sends him to get a biopsy.
read article 



Will Big Data Cure Cancer?

(FORTUNE) Nov 2, 2016 - The Executive Director of the White House’s Cancer Moonshot Task Force isn’t counting on it.
read article 



Flatiron, Foundation Med Link Records of 20,000 Cancer Patients

(Xconomy New York) Nov 3, 2016 - Some of the world’s largest non-profit cancer treatment centers are pooling patient information to gain new insights into the disease and potentially find new treatments. Now two for-profit companies that trade in cancer data are trying the same thing.
read article